

Highlights

Highlights of this edition include:

- Coverage of *PureCircle USA Inc. v. SweeGen, Inc. and Bhagat v. United States Pat. & Trademark Off.*, cases addressing judicial exceptions to patent eligibility of biochemicals. (See § 3:8)
- New section addressing the potential ramifications of artificial intelligence on novelty, nonobviousness, and double patenting. (See § 4:51)
- Expanded discussion of the Supreme Court's decision in *Amgen v. Sanofi*, noting the subsequent *Baxalta* case and the USPTO's issuance of its "Guidelines for Assessing Enablement in Utility Applications and Patents." (See § 5:25)
- Coverage of *Natera, Inc. v. NeoGenomics Lab'ys, Inc.* and the Federal Circuit's adjudication of the claimed infringement of two patents relating to cell-free DNA. (See § 6:11)
- New section on contractor immunity under the Pandemic Readiness and Emergency Preparedness Act. (See § 6:36)